David A. Siegel Metacrine, Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $0.46 $6,405 - $8,418	-18,300 Reduced 29.28%	44,200 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $0.55 $10,922 - $13,970	-25,400 Reduced 28.9%	62,500 $30,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.63 $360 - $630	-1,000 Reduced 1.12%	87,900 $44,000
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $14,190 - $23,100	33,000 Added 59.03%	88,900 $54,000
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $51,520 - $308,315	-80,500 Reduced 59.02%	55,900 $38,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $227,070 - $334,080	87,000 Added 176.11%	136,400 $468,000
Q2 2021 Aug 16, 2021	BUY	$3.37 - $5.73 $129,745 - $220,605	38,500 Added 353.21%	49,400 $188,000
Q1 2021 May 17, 2021	SELL	$6.2 - $11.0 $36,580 - $64,900	-5,900 Reduced 35.12%	10,900 $68,000
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $130,200 - $191,856	16,800 New	16,800 $132,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.